|Seed, 12/2013 ||$3.2M|
DioGenix, Inc. engages in the discovery, development, and commercialization of non-invasive diagnostic, prognostic, and treatment response monitoring tests. Its lead program is designed to provide neurologists with a set of clinical tests to diagnose early-stage MS, segment MS patients into clinical sub-types, and predict response to treatment using non-invasive blood tests. The company was incorporated in 2007 and is based in Gaithersburg, Maryland. As of September 19, 2008, DioGenix, Inc. operates as a subsidiary of Nerveda, Inc.